Combination Therapy for Gout: When Two Medicines Beat One

There is a version of gout treatment where one pill fixes everything. It is not the version most people get. Gout asks two different questions at the same time, and they almost never have the same answer.

The first question is what to do about the joint that is swollen and screaming tonight. The second is what to do about the uric acid that put crystals there in the first place. Anti-inflammatory medicines answer the first. Urate-lowering medicines answer the second. They work on completely separate machinery, which is exactly why they are so often used together rather than instead of each other.

Think of a flare as a fire in one room and high uric acid as the faulty wiring behind the wall. You can put the fire out, and you should. But if you never touch the wiring, another fire is only a matter of time. Combination therapy is simply the decision to deal with both problems, not to pick one and hope. The guideline sets the target for that second job at a serum urate below 6 mg/dL, because that is the level at which crystals stop forming and start to dissolve¹.

For most people, the first combination they meet is not two heavy-hitting drugs. It is one urate-lowering medicine, usually allopurinol, which is the first-line choice for nearly everyone including people with kidney disease², paired with a small daily dose of something anti-inflammatory for the opening stretch.

Here is the part that surprises people. In the first weeks and months after you start lowering your uric acid, flares often get more frequent, not less. As the level in your blood drops, older crystals that had settled quietly in your joints begin to shift and dissolve, and a moving crystal is exactly what your immune system panics over. That is not the medicine failing. It is the medicine working, loudly.

The fix is not to stop. It is to ride out that phase with a low-dose anti-inflammatory alongside the urate-lowering drug. The American College of Rheumatology strongly recommends continuing this prophylaxis for three to six months rather than less, with more time if flares are still happening³. That is the whole logic of the starting combination: cover the joint while the real repair gets underway underneath.

A flare while you are already on urate-lowering therapy can feel like a betrayal. It is not a sign the medicine failed, and it is not a reason to quit. It is the reason to keep flare medicine within reach.

Keep your urate-lowering pill going, at the same dose, and treat the flare on top of it with whatever your clinician has chosen. All three first-line flare options, low-dose colchicine, an NSAID, or a short course of a steroid, are strongly recommended and none is clearly the winner⁴. Which one suits you depends on your kidneys, your stomach, your heart, and what else you take.

The one thing not to do is stop and restart your urate-lowering therapy around a flare. Those swings push your uric acid up and down, and a swinging level is itself a flare trigger. Steady beats stop-start, every time.

If your uric acid is still above target on the highest dose you can tolerate, adding a second urate-lowering drug sounds like the obvious next step. The two main families lower urate in different ways. A xanthine oxidase inhibitor such as allopurinol turns down how much uric acid your body makes, while a uricosuric helps your kidneys flush more of it out⁵. On paper, doing both at once should get you further.

In practice, the guidelines are more cautious than that intuition. When a first xanthine oxidase inhibitor is maxed out and still not reaching target in someone with frequent flares or stubborn tophi, the American College of Rheumatology leans toward switching to a second inhibitor before reaching for a combination⁶. Combining two urate-lowering drugs is a real option, but it is usually not the first thing tried.

Part of the reason is history. The one drug designed specifically to be bolted onto a xanthine oxidase inhibitor was lesinurad, a uricosuric licensed only for use alongside one and capped at 200 mg a day because higher doses raised a kidney safety signal⁷. It has since been withdrawn from the US market by its manufacturer, though it technically remains FDA approved⁸. Probenecid, an older uricosuric that works on the same kidney transporter, is still available and is sometimes paired with an inhibitor.

For a small group of people, oral urate-lowering drugs have genuinely run out of road. When inhibitors and uricosurics have both failed to get someone to target, and they still have frequent flares or tophi that will not resolve, the guideline strongly recommends switching to pegloticase, an infused medicine that dissolves uric acid directly⁹.

Pegloticase has a well-known weakness: in many people the immune system learns to attack it, which blunts the drug and drives up infusion reactions. This is where the best-evidenced combination in all of gout comes in. In the MIRROR trial, adding methotrexate, a medicine that quiets the immune response, alongside pegloticase raised the share of people who reached their urate target from 38.5% to 71.0%, and cut infusion reactions from 30.6% to 4.2%¹⁰.

This is combination therapy at its most deliberate and its most specialist. It is not a first, second, or even third step, and it sits with rheumatology rather than a family doctor. But it is worth knowing it exists, because it is proof that "we have tried everything" is rarely as final as it feels.

When a treatment is not getting you to target, it is easy to read that as a dead end, or as evidence that your gout is uniquely stubborn and untreatable. It almost never is either of those things.

The whole treat-to-target approach is built on the opposite assumption: that if one tool falls short, you adjust the plan rather than abandon it. Sometimes that means a higher dose. Sometimes it means swapping one drug for another. Sometimes it means two medicines working the two different jobs that gout demands. The target does not move, but the route to it can¹.

If you are on a medicine that is not quite doing it, that is information for your next appointment, not a verdict on you. There is almost always a next move. You are not out of options, and you are not behind.